• Channels
    • All News
    • In Focus
    • Special
    • AI
    • Bioregnum
    • Biotech Voices
    • Cell/Gene Tx
    • China
    • Coronavirus
    • Deals
    • Diagnostics
    • Discovery
    • FDA+
    • Financing
    • Health Tech
    • Law
    • Letters to the Editor
    • Manufacturing
    • Marketing
    • Nikkei Biotechnology
    • Opinion
    • Outsourcing
    • Peer Review
    • People
    • Pharma
    • R&D
    • Startups
    • Weekly
  • Webinars
  • Biopharma Jobs
  • More
    • Work at Endpoints
    • Letter to Editors
    • Editorial Standards
    • IPO Tracker
    • Webinars
    • Events
    • Sponsored Posts
    • Advertise
    • Privacy Policy
    • Endpoints Merch
    • About Us
    • Help
  • SIGN UP
  • LOG IN

Neu­ro­science com­pa­ny Rap­port Ther­a­peu­tics lists on Nas­daq

11 months ago
R&D

Ali­gos, Ar­bu­tus and oth­ers tout ear­ly he­pati­tis ef­fi­ca­cy da­ta at #EASL24

11 months ago
R&D

Ipsen re­turns to Maren­go Ther­a­peu­tics for new trispe­cif­ic deal

11 months ago
Deals
R&D

Boehringer In­gel­heim, Zealand tout key fi­bro­sis da­ta from mid-stage MASH tri­al

11 months ago
R&D

Bio­mea’s ear­ly-stage di­a­betes drug put on full clin­i­cal hold, stock crash­es

11 months ago
R&D

Google's par­ent com­pa­ny Al­pha­bet poach­es Eli Lil­ly CFO; More changes at Ex­sci­en­tia

11 months ago
People
Peer Review

Sen­ate fails to pass bill cod­i­fy­ing ac­cess to con­tra­cep­tion

11 months ago
Pharma
FDA+

FDA ex­plains why it re­ject­ed Van­da's in­som­nia ap­pli­ca­tion as com­pa­ny faces takeover bid

11 months ago
Pharma
FDA+

Safe­ty, ef­fi­ca­cy and dos­ing ques­tions linger for Lil­ly's Alzheimer's drug ahead of Mon­day ad­comm

11 months ago
Pharma
FDA+

Nine years and four gener­ics lat­er, the HIV drug at the cen­ter of the Shkre­li con­tro­ver­sy still has a high price

11 months ago
Pharma

Ab­b­Vie gets first taste of Ela­here po­ten­tial with new mid-stage win

11 months ago
R&D
Pharma

J&J’s deal­mak­er: Plen­ty of ‘fire­pow­er,’ but most­ly fo­cused on tuck-in M&A

11 months ago
Deals
Pharma

Mer­ck KGaA’s South Ko­re­an part­ner­ship; Sanofi’s sup­ply chain al­liance with DHL

11 months ago
Manufacturing

Replimune aims for ac­cel­er­at­ed ap­proval of melanoma ther­a­py; Struc­ture's up­sized $476M of­fer­ing

11 months ago
News Briefing

Ex­clu­sive: Wal­mart shut down its health­care clin­ics af­ter loss­es reached near­ly a quar­ter of a bil­lion dol­lars

11 months ago
Health Tech

GSK ac­quires tiny RNA start­up Elsie, boost­ing its grand plans for de­vel­op­ing RNA drugs

11 months ago
Deals

Boehringer In­gel­heim, Zealand’s pos­i­tive Phase 2 MASH fi­bro­sis da­ta ‘un­in­ten­tion­al­ly’ re­leased

11 months ago
R&D

Mod­er­na’s mR­NA can­di­date picked for FDA’s Op­er­a­tion Warp Speed for rare dis­eases

11 months ago
R&D

To pay off debt and stay open, Seres will sell mi­cro­bio­me pill to part­ner Nestlé

11 months ago
Deals

Who are the women mak­ing a mark in bio­phar­ma R&D? Nom­i­nate them for End­points’ 2024 spe­cial re­port

11 months ago
Special

Vir­tu­al phys­i­cal ther­a­py pro­grams can be just as good as in-per­son care, re­port says

11 months ago
Startups
Health Tech

Ger­man ra­dio­phar­ma nabs €188M to boost iso­tope man­u­fac­tur­ing, ad­vance can­cer pipeline

11 months ago
Financing
Manufacturing

For­mer Sanofi R&D leader Frank Nes­tle to lead Deer­field’s grow­ing drug dis­cov­ery arm

11 months ago
People
R&D

Lil­ly ex­ec says de­vel­op­ing new ther­a­pies for lu­pus is 'in scope'

11 months ago
R&D
Pharma
First page Previous page 138139140141142143144 Next page Last page
Endpoints News

Bioscience & Technology Business Center
The University of Kansas
Lawrence, Kansas

Latest

  • All News
  • Special
  • In Focus

Channels

  • AI
  • Bioregnum
  • Biotech Voices
  • Cell/Gene Tx
  • China
  • Coronavirus
  • Deals
  • Diagnostics
  • Discovery
  • FDA+
  • Financing
  • Health Tech
  • Law
  • Letters to the Editor
  • Manufacturing
  • Marketing
  • Nikkei Biotechnology
  • Opinion
  • Outsourcing
  • Peer Review
  • People
  • Pharma
  • R&D
  • Startups
  • Weekly

More

  • Work at Endpoints
  • Letter to Editors
  • Editorial Standards
  • IPO Tracker
  • Events
  • Webinars
  • Sponsored Posts
  • Advertise
  • Endpoints Merch
  • About Us
  • Help

Work in biotech

  • Endpoints Careers

© Endpoints News 2025

  • Help
  • Advertise
  • Privacy Policy
  • Business Model
FT Specialist Logo
A service from the Financial Times